Ask AI
ProCE Banner Activity

Targeting HER2 in Gastric, Colorectal, and Biliary Tract Cancers

Clinical Thought

Read this commentary for practical, real-world insights from experts on HER2 as a therapeutic target across gastrointestinal malignancies, including gastric, colorectal, and biliary tract cancers. Topics addressed include current recommendations for HER2 testing in clinical practice, treatment sequencing, and the implications of emerging data on HER2-targeted therapies within the evolving treatment landscape.

Released: March 05, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Target Audience

This activity is intended for medical oncologists and other healthcare professionals who treat patients with advanced HER2-positive gastric/GEJ cancer, CRC, and BTC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop evidence-based and expert-recommended therapeutic sequencing strategies for patients with advanced HER2-positive gastric/GEJ cancer, CRC, and BTC 

  • Incorporate guideline-recommended HER2 testing and interpretation in clinical practice, encompassing biomarker assessment and the latest clinical evidence for optimal patient care

  • Implement patient-centered and multidisciplinary strategies to proactively manage treatment-related adverse events associated with novel therapies for advanced HER2-positive gastric/GEJ cancer, colorectal cancer (CRC), and biliary tract cancer (BTC)

  • Identify patients most likely to benefit from participation in clinical trials exploring novel HER2-targeted therapies and combinations for gastric/GEJ cancer, colorectal cancer (CRC), and biliary tract cancer (BTC) 

Disclosure

Primary Author

Geoffrey Ku, MD: researcher: AstraZeneca, Bristol Myers Squibb, CARsgen, Daiichi Sankyo, I-Mab, Jazz, Merck, Oncolys, Pieris, Triumvira, Zymeworks; consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, BeOne, Bristol Myers Squibb, Daiichi Sankyo, Gilead, I-Mab, Jazz, Merck, Oncolys, Pieris, Zymeworks; other financial or material support: Dava Oncology, I-Mab.

Kanwal Raghav, MD: consultant: AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eisai, Jazz, Pfizer, Pheon, Seagen; researcher: AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, D3 Bio, Daiichi Sankyo, Eisai, Genentech, Grail, Guardant Health, HiberCell, Innovent, Janssen, MediLink, Merck, Pfizer, UCB BioSciences, Xencor.

Rachna T. Schroff, MD, MS, FASCO: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, Boston Scientific, Elevar, Exelixis, Foundation Medicine, Genentech, J-Pharma Co, Merck, Servier, Syneos Health, Zymeworks; researcher: Actuate, Bristol Myers Squibb, Compass, Exelixis, Faeth, Immuno Vaccine, Lisata, Merck, Seagen.